These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 39110432)

  • 1. Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis.
    Boesjes CM; Kamphuis E; de Graaf M; Spekhorst LS; Haeck I; van der Gang LF; Loman L; Zuithoff NPA; Dekkers C; van der Rijst LP; Romeijn GLE; Oosting AJ; Gostynksi A; van Lynden-van Nes AMT; Tupker RA; van Tuyll van Serooskerken AM; Flinterman A; Politiek K; Touwslager WRH; Christoffers WA; Stewart SM; Kamsteeg M; Schuttelaar MA; de Bruin-Weller MS
    JAMA Dermatol; 2024 Oct; 160(10):1044-1055. PubMed ID: 39110432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Serum Dupilumab Levels at 16 Weeks With Treatment Response and Adverse Effects in Patients With Atopic Dermatitis: A Prospective Clinical Cohort Study From the BioDay Registry.
    Spekhorst LS; de Graaf M; Loeff F; Zuithoff NPA; Bakker D; Boesjes CM; Thijs J; Achten R; van Wijk F; Rispens T; de Bruin-Weller MS
    JAMA Dermatol; 2022 Dec; 158(12):1409-1413. PubMed ID: 36322072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry.
    Zhang J; Boesjes CM; Loman L; Kamphuis E; Romeijn MLE; Spekhorst LS; Haeck I; van der Gang LF; Dekkers CC; van der Rijst LP; Oosting AJ; van Lumig P; van Lynden-van Nes AMT; Tupker RA; Nijssen A; Flinterman A; Politiek K; Touwslager WRH; Christoffers WA; Stewart SM; Kamsteeg M; de Graaf M; de Bruin-Weller MS; Schuttelaar MA
    J Am Acad Dermatol; 2024 Aug; 91(2):300-311. PubMed ID: 38653344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
    Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry.
    Kamphuis E; Boesjes CM; Loman L; Bakker DS; Poelhekken M; Zuithoff NPA; Kamsteeg M; Romeijn GLE; van Wijk F; de Bruin-Weller MS; de Graaf M; Schuttelaar MLA
    Pediatr Allergy Immunol; 2022 Dec; 33(12):e13887. PubMed ID: 36564878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry.
    Spekhorst LS; de Graaf M; Zuithoff NPA; van den Reek JMPA; Kamsteeg M; Boesjes CM; Romeijn GLE; Loman L; Haeck I; Oosting AJ; de Boer-Brand A; Touwslager WRH; Flinterman A; van Lynden-van Nes AMT; Gostynski AH; de Bruin-Weller MS; Schuttelaar ML
    JAMA Dermatol; 2022 Sep; 158(9):1048-1056. PubMed ID: 35947364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
    Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
    Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.
    Ariëns LFM; van der Schaft J; Bakker DS; Balak D; Romeijn MLE; Kouwenhoven T; Kamsteeg M; Giovannone B; Drylewicz J; van Amerongen CCA; Delemarre EM; Knol EF; van Wijk F; Nierkens S; Thijs JL; Schuttelaar MLA; de Bruin-Weller MS
    Allergy; 2020 Jan; 75(1):116-126. PubMed ID: 31593343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.
    Worm M; Simpson EL; Thaçi D; Bissonnette R; Lacour JP; Beissert S; Kawashima M; Ferrándiz C; Smith CH; Beck LA; Chan KC; Chen Z; Akinlade B; Hultsch T; Staudinger H; Gadkari A; Eckert L; Davis JD; Rajadhyaksha M; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Ardeleanu M
    JAMA Dermatol; 2020 Feb; 156(2):131-143. PubMed ID: 31876900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.
    Paller AS; Pinter A; Wine Lee L; Aschoff R; Zdybski J; Schnopp C; Praestgaard A; Bansal A; Shumel B; Prescilla R; Bastian M
    Adv Ther; 2024 Mar; 41(3):1046-1061. PubMed ID: 38194047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
    Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ
    Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry.
    Spekhorst LS; Boesjes CM; Loman L; Zuithoff NPA; Bakker DS; Kamphuis E; Kamsteeg M; Haeck IM; Oosting AJ; van Lumig PPM; van Lynden-van Nes AMT; Tupker RA; Flinterman A; Garritsen FM; Touwslager WRH; de Bruin-Weller MS; Schuttelaar MA; de Graaf M
    Br J Dermatol; 2023 Aug; 189(3):327-335. PubMed ID: 37177895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.
    Bosma AL; de Wijs LEM; Hof MH; van Nieuwenhuizen BR; Gerbens LAA; Middelkamp-Hup MA; Hijnen D; Spuls PI
    J Am Acad Dermatol; 2020 Nov; 83(5):1375-1384. PubMed ID: 32485210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
    Blauvelt A; Teixeira HD; Simpson EL; Costanzo A; De Bruin-Weller M; Barbarot S; Prajapati VH; Lio P; Hu X; Wu T; Liu J; Ladizinski B; Chu AD; Eyerich K
    JAMA Dermatol; 2021 Sep; 157(9):1047-1055. PubMed ID: 34347860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.
    Guttman-Yassky E; Blauvelt A; Eichenfield LF; Paller AS; Armstrong AW; Drew J; Gopalan R; Simpson EL
    JAMA Dermatol; 2020 Apr; 156(4):411-420. PubMed ID: 32101256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Dupilumab in Chinese Elderly Patients with Atopic Dermatitis: A Real-World Study.
    Hu YQ; Zhang JZ; Zhao Y
    Dermatology; 2024; 240(4):589-596. PubMed ID: 38797168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of pathogenic filaggrin variants on dupilumab treatment in atopic dermatitis.
    Clabbers J; Boesjes C; Spekhorst L; van Gisbergen MW; Maas E; Marshall J; Janssen R; Janssen M; Zuithoff N; Steijlen P; de Graaf M; van Geel M; de Bruin-Weller M; Gostyński A
    J Allergy Clin Immunol; 2024 Apr; 153(4):1155-1161.e4. PubMed ID: 38272373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials.
    Paller AS; Silverberg JI; Cork MJ; Guttman-Yassky E; Lockshin B; Irvine AD; Kim MB; Kabashima K; Chen Z; Lu Y; Bansal A; Rossi AB; Shabbir A
    JAMA Dermatol; 2023 Mar; 159(3):255-266. PubMed ID: 36723913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term, observational, real-world study of dupilumab for the treatment of moderate-to-severe atopic dermatitis: a 52-week single-center retrospective analysis in China.
    Deng S; Wang H; Chen Q; Chen X; Song X; Chen S; Kong M; Song Z
    Arch Dermatol Res; 2024 May; 316(6):304. PubMed ID: 38819652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials.
    Silverberg JI; Simpson EL; Ardeleanu M; Thaçi D; Barbarot S; Bagel J; Chen Z; Eckert L; Chao J; Korotzer A; Rizova E; Rossi AB; Lu Y; Graham NMH; Hultsch T; Pirozzi G; Akinlade B
    Br J Dermatol; 2019 Jul; 181(1):80-87. PubMed ID: 30791102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.